Last reviewed · How we verify

Irinotecan liposome、5-Fluorouracil、Leucovorin

Jiangsu HengRui Medicine Co., Ltd. · Phase 3 active Small molecule

Irinotecan liposome、5-Fluorouracil、Leucovorin is a Combination chemotherapy (topoisomerase I inhibitor + antimetabolite) Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd.. It is currently in Phase 3 development for Metastatic colorectal cancer, Pancreatic cancer (in development).

This combination regimen uses liposomal irinotecan (a topoisomerase I inhibitor) plus 5-fluorouracil and leucovorin to inhibit DNA replication and repair in cancer cells.

This combination regimen uses liposomal irinotecan (a topoisomerase I inhibitor) plus 5-fluorouracil and leucovorin to inhibit DNA replication and repair in cancer cells. Used for Metastatic colorectal cancer, Pancreatic cancer (in development).

At a glance

Generic nameIrinotecan liposome、5-Fluorouracil、Leucovorin
SponsorJiangsu HengRui Medicine Co., Ltd.
Drug classCombination chemotherapy (topoisomerase I inhibitor + antimetabolite)
TargetTopoisomerase I; thymidylate synthase
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Irinotecan is a camptothecin derivative that inhibits topoisomerase I, preventing DNA unwinding and causing cell death. The liposomal formulation improves drug delivery and reduces systemic toxicity. 5-Fluorouracil is an antimetabolite that inhibits thymidylate synthase and incorporates into DNA/RNA, while leucovorin (folinic acid) enhances 5-FU efficacy by stabilizing the FdUMP-thymidylate synthase complex.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Irinotecan liposome、5-Fluorouracil、Leucovorin

What is Irinotecan liposome、5-Fluorouracil、Leucovorin?

Irinotecan liposome、5-Fluorouracil、Leucovorin is a Combination chemotherapy (topoisomerase I inhibitor + antimetabolite) drug developed by Jiangsu HengRui Medicine Co., Ltd., indicated for Metastatic colorectal cancer, Pancreatic cancer (in development).

How does Irinotecan liposome、5-Fluorouracil、Leucovorin work?

This combination regimen uses liposomal irinotecan (a topoisomerase I inhibitor) plus 5-fluorouracil and leucovorin to inhibit DNA replication and repair in cancer cells.

What is Irinotecan liposome、5-Fluorouracil、Leucovorin used for?

Irinotecan liposome、5-Fluorouracil、Leucovorin is indicated for Metastatic colorectal cancer, Pancreatic cancer (in development).

Who makes Irinotecan liposome、5-Fluorouracil、Leucovorin?

Irinotecan liposome、5-Fluorouracil、Leucovorin is developed by Jiangsu HengRui Medicine Co., Ltd. (see full Jiangsu HengRui Medicine Co., Ltd. pipeline at /company/jiangsu-hengrui-medicine-co-ltd).

What drug class is Irinotecan liposome、5-Fluorouracil、Leucovorin in?

Irinotecan liposome、5-Fluorouracil、Leucovorin belongs to the Combination chemotherapy (topoisomerase I inhibitor + antimetabolite) class. See all Combination chemotherapy (topoisomerase I inhibitor + antimetabolite) drugs at /class/combination-chemotherapy-topoisomerase-i-inhibitor-antimetabolite.

What development phase is Irinotecan liposome、5-Fluorouracil、Leucovorin in?

Irinotecan liposome、5-Fluorouracil、Leucovorin is in Phase 3.

What are the side effects of Irinotecan liposome、5-Fluorouracil、Leucovorin?

Common side effects of Irinotecan liposome、5-Fluorouracil、Leucovorin include Neutropenia, Diarrhea, Nausea/vomiting, Anemia, Fatigue, Mucositis.

What does Irinotecan liposome、5-Fluorouracil、Leucovorin target?

Irinotecan liposome、5-Fluorouracil、Leucovorin targets Topoisomerase I; thymidylate synthase and is a Combination chemotherapy (topoisomerase I inhibitor + antimetabolite).

Related